References
[1] GUO C, MANJILI M H, SUBJECK J R, et al.Therapeutic cancer vaccines: past, present,and future[J].Advances in cancer research, 2013,119:421-475.
[2] MCBRIDE W H, THACKER J D, COMORA S, et al.Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity[J].Cancer research, 1992,52(14):3931-3937.
[3] BERGER M, KREUTZ F T, HORST J L, et al.Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer[J].Journal of pharmacy &pharmaceutical sciences, 2007,10(2):144-152.
[4] DRANOFF G, JAFFEE E, LAZENBY A, et al.Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity[C]//Proceedings of the National Academy of Sciences of the United States of America, 1993,90(8):3539-3543.
[5] BURKHARDT U E, HAINZ U, STEVENSON K, et al.Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells[J].The journal of clinical investigation,2013,123(9):3756-3765.
[6] DRANOFF G .GM-CSF-based cancer vaccines[J].Immunological reviews, 2002,188:147-154.
[7] ROSSI G R, MAUTINO M R, UNFER R C, et al.Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes[J].Cancer research, 2005,65(22):10555-10561.
[8] BERD D.M-Vax: an autologous, hapten-modified vaccine for human cancer[J].Expert review of vaccines, 2004,3(5):521-527.
[9] MELLMAN I.Dendritic cells: master regulators of the immune response[J].Cancer immunology research, 2013,1(3):145-149.
[10] FENTON R G, TURCOVSKI-CORRALES S M, TAUB D D.Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines[J].Journal of immunotherapy.1998,1(2):95-108.
[11] NESTLE F O, ALIJAGIC S, GILLIET M, et al.Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells[J].Nature medicine, 1998,4(3):328-332.
[12] RIDOLFI L, PETRINI M, FIAMMENGHI L, et al.Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis[J].Clinical & developmental immunology,2010,2010:504979.
[13] BROWER V.Approval of provenge seen as first step for cancer treatment vaccines[J].Journal of the National Cancer Institute, 2010,102(15):1108-1110.
[14] LU L, TAO H, CHANG A E, et al.Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells[J].Oncoimmunology,2015,4(3): e990767.
[15] KARBACH J, GNJATIC S, BENDER A, et al.Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival[J].International journal of cancer, 2010,126(4):909-918.
[16] TSUJI T, SABBATINI P, JUNGBLUTH A A, et al.Effect of montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial[J].Cancer immunology research, 2013,1(5):340-350.
[17] FRANÇOIS V, OTTAVIANI S, RENKVIST N, et al.The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells[J].Cancer research, 2009,69(10):4335-4345.(https://www.daowen.com)
[18] VANSTEENKISTE J, ZIELINSKI M, LINDER A, et al.Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results[J].Journal of clinical oncology, 2013,31(19):2396-2403.
[19] VANSTEENKISTE J F, CHO B C, VANAKESA T, et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled,phase 3 trial[J].The lancet oncology, 2016,17(6):822-835.
[20] WOOD C G, MULDERS P.Vitespen: a preclinical and clinical review[J].Future oncology,2009,5(6):763-774.
[21] RICE J, OTTENSMEIER C H, STEVENSON F K.DNA vaccines: precision tools for activating effective immunity against cancer[J].Nature reviews cancer, 2008,8(2):108-120.
[22] Yang B, Jeang J, Yang A, et al.DNA vaccine for cancer immunotherapy[J].Human vaccines& immunotherapeutics, 2014,10(11):3153-3164.
[23] SMITH A D.Videourology: an historical perspective and a view to the future[J].Journal of endourology, 2010,24(2):165-166.
[24] LIU M A, ULMER J B.Human clinical trials of plasmid DNA vaccines[J].Advances in genetics, 2005,55:25-40.
[25] RIBAS A, WEBER J S, CHMIELOWSKI B, et al.Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial[J].Clinical cancer research, 2011,17(9):2987-2996.
[26] AURISICCHIO L, CILIBERTO G .Emerging cancer vaccines: the promise of genetic vectors[J].Cancers (Basel), 2011,3(3):3687-3713.
[27] DIAZ C M, CHIAPPORI A, AURISICCHIO L, et al.Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors[J].Journal of translational medicine, 2013,11:62.
[28] CHUDLEY L, MCCANN K, MANDER A, et al.DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time[J].Cancer immunology immunotherapy, 2012,61(11):2161-2170.
[29] MORSE M A, CHAUDHRY A, GABITZSCH E S, et al.Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients[J].Cancer immunology, immunotherapy, 2013,62(8):1293-1301.
[30] MCNAMARA M A, NAIR S K, HOLL E K.RNA-Based vaccines in cancer immunotherapy[J].Journal of immunology research, 2015,2015:794528.
[31] FOTIN-MLECZEK M, ZANZINGER K, HEIDENREICH R, et al.Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect[J].The journal of gene medicine, 2012,14(6):428-439.
[32] KÜBLER H, SCHEEL B, GNAD-VOGT U, et al.Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study[J].Journal for immunotherapy of cancer, 2015,3:26.
[33] Ying H, Zaks T Z, Wang R F, et al.Cancer therapy using a self-replicating RNA vaccine[J].Nature medicine, 1999,5(7):823-827.